Purpose: To analyze the minimum inhibitory concentration (MIC) of isolates from fungal keratitis to natamycin and voriconazole and to assess the relationship between organism, MIC, and clinical outcome.
F ungal keratitis is an important cause of visual loss globally. 1 Some locations report that as many as 50% of their corneal ulcers are fungal in etiology. [2] [3] [4] [5] Fungal corneal ulcers are difficult to treat and typically cause more severe vision impairment than bacterial corneal ulcers. 6 Treatment of fungal corneal ulcers is largely empirical, and the role of susceptibility testing in guiding treatment decisions is unclear. An important question in the treatment of fungal corneal ulcers is therefore whether antifungal susceptibilities of fungal isolates correlate with clinical outcomes. Previous reports indicate that minimum inhibitory concentrations (MICs) may be correlated with clinical outcomes in ocular bacterial and fungal infections; however, larger prospective studies are required to confirm this. [7] [8] [9] Triazoles, including voriconazole, have good in vitro activity against isolates from fungal corneal ulcers, but there are conflicting reports about their activity against Fusarium spp. 10, 11 In this study, we report the in vitro activity of natamycin and voriconazole against clinical isolates collected as part of a randomized, controlled, clinical trial 12 and investigate how organism and MIC correlate with acuity, scar size, reepithelialization time, and perforation.
METHODS
The Mycotic Ulcer Treatment Trial Therapeutic Exploratory Study was a randomized, controlled, double-masked, clinical trial investigating whether natamycin or voriconazole, with or without repeated scraping, results in better visual outcomes 3 months after presentation. Specific methods for the trial have been described previously. 12 Ethics approval was obtained from the University of California, San Francisco, Committee on Human Research, Dartmouth Medical School, and Aravind Eye Care System, Madurai.
Main outcome measures for this study included best spectacle-corrected visual acuity (BSCVA) at 3 weeks and 3 months from enrollment, infiltrate/scar size at 3 weeks and 3 months, time to reepithelialization, and proportion of patients with a corneal perforation. Patients were followed every 3 days (±1 day) until reepithelialization. BSCVA was assessed at enrollment, 3 weeks, and 3 months by masked refractionists using an Early Treatment Diabetic Retinopathy Study chart. Infiltrate/scar size and epithelial defect size were measured as the longest dimension followed by the longest perpendicular to that dimension by masked examiners on slit-lamp examination at each study visit. Reepithelialization was defined as an epithelial defect ,0.5 mm with the administration of fluorescein. The depth of the infiltrate was assessed by slit-lamp examination and was divided into 1 of 4 categories: no infiltrate/scar, .0% to 33%, .33% to 67%, or .67% depth. Perforation was defined as a corneal ulcer that extends through the full thickness of the cornea, extending into the anterior chamber. Specific signs of perforation, such as a flat anterior chamber, iris plugging a corneal hole, intraocular pressure #4 mm Hg, and a positive Seidel test, were assessed at each study visit. All patients were assessed for adverse events, including corneal perforation, at each study visit. Patients with an existing perforation or impending perforation were excluded from the trial. Impending perforation was defined as the presence of a descemetocele. Before the start of the study, all observers and refractionists were trained in specific methods for the study and certified. Every tenth patient had a repeat examination performed by a second observer. All observers were masked to MIC measurements because examinations and visual acuity measurements were performed before the availability of MIC results. Laboratory personnel were masked to examination and visual acuity results.
Microbiology
Corneal scrapings were obtained from all patients who were eligible for the trial, and Gram stains and potassium hydroxide (KOH) wet mounts were performed. Patients were considered for inclusion in the trial if they had a KOH wet mount positive for fungus and a Gram stain negative for bacteria. Scrapings were also inoculated onto sheep blood agar, chocolate agar, and either potato dextrose agar or Sabouraud agar for fungal and bacterial cultures. Fungal cultures were determined to be positive if there was growth on 2 or more media or if there was moderate-to-heavy growth on 1 medium. Fungal identification was performed using gross and microscopic characteristics, as previously described. 5, 13 Antifungal susceptibility testing for natamycin and voriconazole was performed on all samples that had a positive fungal culture according to standardized methods outlined in the Clinical and Laboratory Standards Institute document M38-A2. 10, 14 MIC was defined as the lowest concentration that exhibited a 100% visual reduction in turbidity when compared with the control tube for natamycin, and an 80% reduction in turbidity for voriconazole. 14 Only natamycin and voriconazole were analyzed because these were the treatments studied in the clinical trial. MIC 50 and MIC 90 were estimated as the median and 90th percentile (PERCENTILE function in Microsoft Excel; Microsoft, Inc, Redmond, WA).
Statistical Analyses
A log 2 transformation of MIC was used for all statistical models. The association between MIC and BSCVA at 3 weeks and 3 months was analyzed with linear regression controlling for baseline visual acuity and treatment arm. Infiltrate/scar size at 3 weeks and 3 months was analyzed with linear regression controlling for baseline scar size and treatment arm. Perforation was analyzed by logistic regression controlling for enrollment depth of the ulcer and treatment arm. Time to reepithelialization was analyzed with a Cox proportional hazards model, controlling for baseline epithelial defect size, treatment assignment, and whether the patient had rescraping. Organism and MIC were analyzed with 1-way analysis of variance. Organism and outcomes were analyzed with 1-way analysis of variance for continuous outcomes (BSCVA and infiltrate/scar size), log-rank test for time to reepithelialization, and Fisher exact test for perforation. Means for continuous variables were compared with a t test. All statistical analyses were conducted using Stata 10.0 (Stata Corporation, College Park, TX). Isolates with more than 1 organism identified were excluded from the analysis (n = 2).
RESULTS
Of the 120 patients enrolled in the trial, 101 (84%) had a positive fungal culture available for analysis of MIC. Of these, 84 samples had an identifiable organism with more than 1 observation per organism and could be used for calculation of MIC 50 and MIC 90 . Thirteen patients (16%) were on a topical antifungal at presentation: 9 were on topical natamycin (11%) and 4 were on topical fluconazole (5%). Of the 84 patients with identifiable organisms, 52 (62%) were judged to have an enrollment depth of 0% to 33%, 21 (25%) had enrollment depth of 33% to 67%, and 11 (13%) had an enrollment depth of .67%. The most common genus of fungus was Fusarium (n = 44), followed by Aspergillus (n = 17) (Table 1 ). Because the samples were collected as part of a clinical trial, prospectively collected clinical data were available for all isolates. Although there were no statistically significant differences across the groups of organism, Aspergillus spp had the worst visual acuity at 3 weeks and 3 months, with Aspergillus flavus having worse visual acuity at 3 months than Aspergillus fumigatus. Aspergillus spp also had the largest infiltrate/scar size at 3 months. A. fumigatus had the highest rate of perforations and the longest time to reepithelialization ( Table 1 ). Patients with isolates that did not grow on culture had significantly worse mean BSCVA than patients whose isolates did grow on culture at baseline [1.2 logarithm of the minimum angle of resolution (logMAR) vs. 0.88 logMAR; P = 0.02], 3 weeks (1.14 logMAR vs. 0.67 logMAR; P = 0.01), and 3 months (0.82 logMAR vs. 0.49 logMAR; P = 0.04).
Organism Versus MIC
MIC 50 and MIC 90 for each genus of organism are listed in Table 1 . The MIC 50 for natamycin was equal to or higher than voriconazole for all organisms; the MIC 90 for natamycin was higher for all organisms except Fusarium and Bipolaris spp (Fig. 1 ). The MIC for voriconazole was lowest for Aspergillus spp. Organism and MIC were significantly different across groups of organisms (P = 0.0001).
MIC Versus Outcome
Analyses of the association between MIC and individual outcomes (BSCVA, infiltrate/scar size, perforation, and time to reepithelialization) are listed in Table 2 . Corneal perforation was the only outcome significantly associated with MIC, with isolates with higher MICs coming from corneal ulcers that were more likely to perforate (odds ratio, 2.03; 95% CI, 1.02-4.04; P = 0.04). The median MIC in patients who perforated was 8 mg/mL [interquartile range (IQR) 4-8 mg/mL], compared with a median MIC of 4 mg/mL (IQR, 2-8 mg/mL) in patients who did not perforate. Median time to perforation was 17 days (IQR, 13-19 days).
DISCUSSION
Fungal keratitis is an increasingly important cause of visual loss globally. 6 In tropical climates, such as South India, a large portion of cases of keratitis are caused by fungus. 4, 5 Although the incidence of fungal keratitis remains relatively low in the United States, the United Kingdom, and other temperate climates, there is some evidence that the incidence may be increasing, particularly contact lens-related fungal keratitis. 15, 16 In this study, the majority of fungal pathogens isolated were Fusarium spp or Aspergillus spp. Previous studies in India have shown that Fusarium and Aspergillus are both common causative organisms of fungal keratitis. 2, 4, 5, 10 Although fungal keratitis due to yeast may be more common in temperate climates, both Fusarium and Aspergillus are important organisms in filamentous fungal keratitis globally. 3, [15] [16] [17] [18] [19] [20] Different fungal pathogens may result in a more or less severe course of disease. A previous study in South India showed that the genus Aspergillus was significantly associated with primary treatment failure. 21 Similarly, in this group of patients, Aspergillus spp produced the worst visual acuity and the largest infiltrate/scar size at 3 months, highest rate of perforation, and longest time to reepithelialization; however, these differences were not statistically significant. Of note, fewer patients with Aspergillus spp were randomized to receive voriconazole than natamycin. In vitro, voriconazole had a lower MIC against Aspergillus spp than natamycin and appeared to have better activity against Aspergillus spp than any other organism. A larger sample size may be needed to determine if organism is significantly associated with outcomes, and how MIC mediates this association.
MICs were analyzed only for natamycin and voriconazole because these were the treatments under study in the clinical trial in which the samples were collected. 12 Absolute MICs for natamycin overall were higher for all organisms than MICs for voriconazole, with the exception of Fusarium spp, which had a higher MIC 90 for voriconazole. In this study, Fusarium spp had a higher MIC 90 for voriconazole than has been previously reported. 10, 11 These results are not adjusted for available dose; natamycin is commercially available in 5% concentration, whereas voriconazole is prepared at 1% concentration. However, natamycin has been shown to have poor penetration through an intact epithelium, whereas voriconazole may have better penetration. [22] [23] [24] These differences in dosage and penetration may change the available dose and affect the efficacy of the medication.
We noted a significant association between corneal perforation and higher MIC. Ulcers caused by organisms that had higher MICs were more likely to perforate. In systemic bacterial infections, in vitro susceptibility is thought to predict the response of bacterial infections according the "90 to 60 rule," which states that susceptible organisms respond 90% of the time, and resistant organisms respond 60% of the time. 25, 26 More recently, a similar predictive utility has been suggested for systemic fungal infections, and susceptibility testing is an increasingly used tool for managing these infections. 25 A previous study in South India, on a different set of cases, demonstrated that a lower MIC was significantly associated with a good outcome, defined as a healing time of less jjHazards ratio. than 3 weeks. 8 In systemic fungal infections, lower MICs have been shown to correlate with successful outcomes. 25, 27 In our study, it seemed that a lower MIC correlated with a successful outcome (no perforation). Visual acuity, infiltrate/scar size, and time to reepithelialization seemed to be improved with lower MICs; however, this difference was not significant. Organisms that are more susceptible to antifungal treatment may respond more quickly to these therapies, clearing the infection more quickly and allowing the ulcer to heal, thus reducing the time to reepithelialization and decreasing the likelihood of perforation. In this study, we assessed how the ulcers responded during the course of treatment by controlling for baseline characteristics. The median time to perforation was 17 days, indicating that these perforations were occurring after several weeks of appropriate therapy. This study therefore suggests that MIC may play a role in assessing whether an ulcer progresses to perforation. A previous study of bacterial corneal infections showed that lower MICs were associated with a smaller infiltrate/scar size at 3 months. 7 Although cases with lower MICs tended to have lower infiltrate/scar sizes, this association was not statistically significant in this population. Many factors play a role in the healing of a corneal ulcer, in addition to the effectiveness of the antimicrobial. A larger sample size may be needed to demonstrate whether there is a true association between visual acuity and infiltrate/scar size and MIC.
Although 1% voriconazole (10,000 mg/mL) is released on the corneal surface, concentrations of voriconazole in the cornea are likely to be substantially lower than the concentration of drug as prepared. Aqueous concentrations of voriconazole have been found to be between 0.61 and 6.94 mg/mL, depending on dosing schedules and administration. 22, 24, 28 In this study, MIC 50 for voriconazole was between 0.5 and 4 mg/mL depending on the organism, which is generally lower than these aqueous concentrations, given our dosing schedule for the trial of 1 drop of voriconazole 1% every 1 hour while awake for 1 week and then 1 drop every 2 hours while awake until 3 weeks from enrollment. 12 The association seen between MIC and clinical outcome suggests that aqueous concentrations of the drug were similar to what has previously been reported. Corneal penetration of natamycin is poor in the presence of an intact epithelium, although debridement is thought to increase its penetration. 23 Voriconazole may penetrate deeper into the corneal stroma, thus achieving therapeutic concentrations more efficiently. 28 Limitations of this study include a small sample size for many of the organisms identified. Making comparisons across groups of organisms is difficult when there are small numbers for some of the organisms identified. Second, the criterion for a fungal positive ulcer for enrollment in the trial was evidence of filamentous fungus on smear, and therefore not all of the patients had an identifiable organism that grew on culture. Patients with no growth on culture had significantly worse baseline, 3-week, and 3-month visual acuity and significantly larger 3-month infiltrate/scar size. It is impossible to know how nonculturable organisms might affect results. We did not collect detailed information on patient compliance to medications in the trial. It is unknown whether patients had different compliance patterns based on the drug they were randomized to or the course of their ulcer. Any difference in compliance could potentially bias results. Finally, patients with an impending perforation were excluded from the trial. Clinical outcomes for these patients are not known, nor are the MICs to voriconazole or natamycin known. This study investigated how MIC affected how ulcers responded during the course of treatment. Inclusion of ulcers with impending perforation would have added minimal treatment information and may have biased outcomes.
In this study, we describe the organisms collected in a fungal corneal ulcer clinical trial in South India and their susceptibilities to natamycin and voriconazole, the treatments investigated in the trial. MIC and organism were found to be significantly associated. In addition, we found that there is a higher likelihood of perforation in the ulcers with organisms that were more resistant to the antifungal they were treated with. Although a larger sample size is needed to confirm these results and to demonstrate if MIC is associated with visual acuity, infiltrate/scar size, and reepithelialization time, our results suggest that high MIC may be associated with worse prognoses. This has implications for the potential role of MIC data in guiding therapeutic decisions in the management of mycotic keratitis. Our study suggests that resistant strains of fungus lead to poor outcomes in fungal keratitis, emphasizing the need for the development and study of new antifungal strategies.
